8 results about "Epileptic disorder" patented technology

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. The compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. The use of compound C having formula (I'), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the preparation of pharmaceutical compositions for the treatment or prevention of disorders for which ASIC inhibitors are indicated is also provided. In some embodiments, pharmaceutical compositions prepared using the compound of formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or compound C, are for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511139000245.jpg21170

Provided are crystalline forms of 3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine, pharmaceutical compositions comprising the crystalline form, and their use in treating conditions associated with TARP γ8-dependent AMPA activity, such as epilepsy, epileptic disorders, seizures, seizure disorders, pain, psychiatric diseases, or neurodegenerative diseases.

Provided, inter alia, are methods for treating an epilepsy disorder using clemizole, a clemizole analog, or pharmaceutical salts thereof.

Artificial expression constructs for modulating gene expression in targeted central nervous system cell types are described. The artificial expression constructs can be used in the assessment and / or treatment of epileptic disorders.

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. Pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, diluent, or excipient are also provided. Compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or pharmaceutical compositions comprising them, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. In some embodiments, compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or pharmaceutical compositions comprising them, may be used for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511124000359.jpg20170

The present application relates to methods and compositions for treating epileptic disorders. The use of allosteric modulators and / or gaboxadol for treating an epileptic disorder in a subject in need thereof.

The present disclosure provides, in part, methods of treating an epileptic disorder in a pediatric subject in need thereof, the methods comprising administering to the pediatric subject rilapladib; the present disclosure provides pharmaceutical compositions comprising rilapladib and a pharmaceutically acceptable excipient and methods of use thereof in the treatment of disorders, such as epileptic disorders.